Merck and Moderna’s Positive Phase 3 Cancer Vaccine Data Reshape the Oncology Trade
Merck’s Keytruda gains and Moderna’s 9% stock pop highlight two distinct oncology narratives: established scale and potential mRNA growth.
Pfizer’s TUKYSA FDA Approval Opens a New Frontline Breast Cancer Growth Opportunity
Pfizer’s frontline FDA approval for TUKYSA could broaden its oncology opportunity as investors assess the company’s post-COVID pipeline.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
Perrigo Takeover Chatter Puts PRGO Shares on M&A Watch
Reported takeover interest has put Perrigo and its PRGO shares in the spotlight, but no buyer, offer price or deal terms…
Moderna and Merck Cancer Vaccine Trial Success Puts MRNA and MRK in Focus
Phase 3 melanoma data from Moderna and Merck may strengthen the case for mRNA oncology and add strategic value to Keytru…
Teva Hits 52-Week High as FDA Clears First Once-Monthly Schizophrenia Injection
Teva’s WELTRUZA approval gives investors a potential specialty-medicine catalyst as the company advances its branded-pha…
XORTX Therapeutics Shares Jump 16.7% as Gout Program Moves Toward IND Filing
XORTX Therapeutics shares traded up 16.7% after news that its gout program is advancing toward an IND submission.
Bristol Myers Squibb’s Positive Zenbexus Data Put Multiple Myeloma Pipeline in Focus
Bristol Myers Squibb reported positive Phase 3 Zenbexus data, putting its multiple myeloma pipeline and potential regula…
Teva Shares Rise Premarket After FDA Approves Once-Monthly Schizophrenia Treatment
Teva's ADRs climbed 4.5% premarket after FDA approval, putting its neuroscience pipeline and turnaround execution in foc…
XORTX Therapeutics Jumps 16.7% as Gout Drug Program Moves Toward IND Filing
XORTX Therapeutics shares rose 16.7% as traders responded to progress toward an IND filing for the company’s accelerated…
FDA Expands Tecentriq Use to Stage III Colon Cancer in Roche Oncology Boost
FDA approval of Tecentriq in stage III colon cancer expands Roche’s oncology opportunity and adds a new competitive angl…
Teva Shares Rise as FDA Approves Once-Monthly Weltruza Schizophrenia Treatment
Teva shares rose 3.5% to 4.5% premarket after FDA approval of once-monthly Weltruza, sharpening focus on its specialty-m…